N. Raje

B563 Anti-DKK1 mAb (BHQ880) as a Potential Therapeutic Agent for Multiple Myeloma

Mariateresa Fulciniti, Sonia Vallet, Seth A. Ettenberg et al. · Clinical Lymphoma & Myeloma · 2009 · 28 citations

Hematological Malignancy, Potential Therapeutic Agent, Medicine +7

Safety and efficacy of lenalidomide (Len), bortezomib (Bz), and dexamethasone (Dex) in patients (pts) with newly diagnosed multiple myeloma (MM): A phase I/II study

Paul G. Richardson, Sagar Lonial, Andrzej Jakubowiak et al. · Journal of Clinical Oncology · 2008 · 23 citations

Phase I/ii Study, Pharmacotherapy, Pharmacodynamic Modeling +19

Clinical remissions and limited toxicity in a first-in-human multicenter study of bb2121, a novel anti-BCMA CAR T cell therapy for relapsed/refractory multiple myeloma

Jesús G. Berdeja, Yi Lin, N. Raje et al. · European Journal of Cancer · 2016 · 13 citations

Hematological Malignancy, Medicine, Clinical Remissions +9

Phase II study of lenalidomide (Len), bortezomib (Bz), and dexamethasone (Dex) in patients (pts) with relapsed or relapsed and refractory multiple myeloma (MM)

Kenneth C. Anderson, Sundar Jagannath, Andrzej Jakubowiak et al. · Journal of Clinical Oncology · 2008 · 13 citations

Relapsed/refractory Mm, Pathology, Phase Ii Study +16

Phase I study of LY2127399, a human anti-BAFF antibody, and bortezomib in patients with previously treated multiple myeloma.

N. Raje, Raymond J. Hohl, Edward A. Faber et al. · Journal of Clinical Oncology · 2011 · 12 citations

Human Mab, Immunology, Pathology +22